Skip to main content
DXCM logo
DXCM
(NASDAQ)
DexCom, Inc.
$71.44-- (--)
Loading... - Market loading

DexCom (DXCM) Company Profile

Complete business overview, executive team, trading details, and corporate information.

DexCom, Inc.
DXCMNasdaq Stock Market

About DexCom

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Company Information

CEOJacob Leach
Founded1999
Employees11,050
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNasdaq Stock Market (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Phone858 200 0200
Address
6340 Sequence Drive San Diego, California 92121 United States

Corporate Identifiers

CUSIP252131107
ISINUS2521311074
SIC3845

Leadership Team & Key Executives

Jacob Leach
Chief Executive Officer
Jereme Sylvain
Chief Financial Officer
Sean Christensen
Head of Investor Relations